England – Talk Bio

NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease

3 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, Clustered Regularly Interspaced Short Palindromic Repeats, England, exagamglogene autotemcel, gene therapy, Nance-Horan syndrome, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution

Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval

Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach

5 months ago talkbio0Tagged Access, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss Medication

Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.

NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo

5 months ago talkbio0Tagged AstraZeneca, Daiichi, England, Enhertu, Malignant neoplasm of breast, Nance-Horan syndrome, NHS, Nitroglycerin/Sodium Citrate/Ethanol Solution, Sankyo

Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England

NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach

7 months ago talkbio0Tagged Eli, Eli Lilly, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss

NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

AstraZeneca Commits £650M Expansion for UK Vaccine Hub and Research Campus

1 year ago talkbio0Tagged AstraZeneca, Cambridge/, Economic Growth, England, Environment, Government support, Investments, Life sciences sector, Occupations, operationally, pandemic preparedness, public health protection, Renewable Energy, research, Research and Development, Speke/ Liverpool, Surgical construction, Taxes, UK vaccine

AstraZeneca, £650 million investment, UK vaccine hub, Speke/ Liverpool, Renewable energy, Operationally net-zero facility, Research and Development (R&D) campus, Cambridge/ England, Job creation, Pandemic preparedness, Public health protection, Economic growth, Government support, Tax environment, Life sciences sector